Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.62 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.62 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 4/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401878 | 0.92 | CYP4F2 (0.68) | CYP4F2CYP4A11CYP4Z1LMNAL3MBTL1 | |
| SCHEMBL4142310 | 0.84 | TBXAS1 (0.52) | CYP4Z1MAPTKMT2A | |
| SCHEMBL490909 | 0.84 | CYP4F2 (0.70) | CYP4F2CYP4A11CYP4Z1LMNAL3MBTL1 | |
| SCHEMBL68902 | 0.83 | CYP4F2 (0.85) | CYP4F2CYP4A11CYP4Z1LMNAL3MBTL1 | |
| SCHEMBL12000868 | 0.83 | CYP4F2 (0.64) | CYP4F2CYP4A11CYP4Z1LMNAL3MBTL1 | |
| SCHEMBL23074519 | 0.83 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP4Z1LMNAL3MBTL1 | |
| SCHEMBL10729323 | 0.83 | PPARA (0.56) | CYP4F2CYP4A11L3MBTL1MAPTFFAR1 | |
| SCHEMBL4889783 | 0.82 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1LMNAL3MBTL1 | |
| SCHEMBL16695953 | 0.82 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1LMNAL3MBTL1 | |
| SCHEMBL873598 | 0.81 | LMNA (0.55) | LMNAL3MBTL1MAPTFFAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884836-B2 | 2-substituted-5-hydroxy-4H-chromen-4-ones as novel ligands for the serotonin receptor 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-02-02 | — | — | US | disclosed |
| WO-2015116460-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | HTR2B, HTR3B, HTR4 | CYP4F2 344/4885CYP4A11 342/4885CYP4Z1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.